Siri Carpenter is an award-winning science writer and editor based in Madison, Wisconsin. Her work has appeared in The New York Times, The Los Angeles Times, The Washington Post, O: the Oprah Magazine, Science, Scientific American Mind, Science News, and many other publications. She’s first author on the psychology textbook Visualizing Psychology (John Wiley & Sons, 2007). She is also co-founder and editor-in-chief of The Open Notebook, a nonprofit organization and website that provides resources to help science journalists improve their skills.
Siri Carpenter
Freelance Writer
Spectrum
From this contributor
The children who leave autism behind
Some children shed the symptoms of autism and eventually lose their diagnosis. What sets them apart?
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.